A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma
Abstract Pembrolizumab with cisplatin and 5‐fluorouracil showed survival benefit but relatively high occurrence of treatment‐related adverse events (TRAEs) for recurrent/metastatic oral squamous cell carcinoma (R/M OSCC). A more tolerable regime is needed. This trial enrolled 20 R/M OSCC patients wi...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.312 |
| _version_ | 1797693077072117760 |
|---|---|
| author | Houyu Ju Dongliang Wei Yunteng Wu Yang Liu Qi Ding Mengyu Rui Zongyu Fan Yanli Yao Jingzhou Hu Guoxin Ren |
| author_facet | Houyu Ju Dongliang Wei Yunteng Wu Yang Liu Qi Ding Mengyu Rui Zongyu Fan Yanli Yao Jingzhou Hu Guoxin Ren |
| author_sort | Houyu Ju |
| collection | DOAJ |
| description | Abstract Pembrolizumab with cisplatin and 5‐fluorouracil showed survival benefit but relatively high occurrence of treatment‐related adverse events (TRAEs) for recurrent/metastatic oral squamous cell carcinoma (R/M OSCC). A more tolerable regime is needed. This trial enrolled 20 R/M OSCC patients with previously untreated and PD‐L1 positive. Patients were administered camrelizumab with docetaxel and cisplatin every 3 weeks for six cycles, followed by camrelizumab monotherapy every 3 weeks until disease progression or intolerable toxicity. The primary endpoint was occurrence of grade ≥ 3 TRAEs, secondary endpoints included overall survival (OS), progression‐free survival (PFS), and overall response rate (ORR). 45% patients experienced grade ≥ 3 TRAEs, which the most common were anemia (15%), stomatitis (15%), and neutropenia (10%). The most common potential immune‐related adverse events were reactive cutaneous capillary endothelial proliferation (RCCEP; 60%), hypothyroidism (35%), and pneumonitis (15%). No treatment‐related deaths occurred. The median OS, PFS, and ORR was 14.4 months, 5.35 months, and 40.0% respectively. The study also found RCCEP occurrence, lower FOXP3+ cells, and higher density of intratumor tertiary lymphoid structure were associated with improved efficacy. Our data suggest that camrelizumab with docetaxel/cisplatin as first‐line therapy was well tolerable and had potentially favorite efficacy in PD‐L1‐positive patients with R/M OSCC. |
| first_indexed | 2024-03-12T02:38:22Z |
| format | Article |
| id | doaj.art-77f31d554da740e3903d08f5f86ade96 |
| institution | Directory Open Access Journal |
| issn | 2688-2663 |
| language | English |
| last_indexed | 2024-03-12T02:38:22Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | MedComm |
| spelling | doaj.art-77f31d554da740e3903d08f5f86ade962023-09-04T11:20:36ZengWileyMedComm2688-26632023-08-0144n/an/a10.1002/mco2.312A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinomaHouyu Ju0Dongliang Wei1Yunteng Wu2Yang Liu3Qi Ding4Mengyu Rui5Zongyu Fan6Yanli Yao7Jingzhou Hu8Guoxin Ren9Department of Oral Maxillofacial‐Head and Neck Oncology Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Oral Maxillofacial‐Head and Neck Oncology Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Oral Maxillofacial‐Head and Neck Oncology Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Oral Maxillofacial‐Head and Neck Oncology Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Oral Maxillofacial‐Head and Neck Oncology Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Oral Maxillofacial‐Head and Neck Oncology Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Oral Maxillofacial‐Head and Neck Oncology Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Oral Maxillofacial‐Head and Neck Oncology Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Oral Maxillofacial‐Head and Neck Oncology Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Oral Maxillofacial‐Head and Neck Oncology Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai ChinaAbstract Pembrolizumab with cisplatin and 5‐fluorouracil showed survival benefit but relatively high occurrence of treatment‐related adverse events (TRAEs) for recurrent/metastatic oral squamous cell carcinoma (R/M OSCC). A more tolerable regime is needed. This trial enrolled 20 R/M OSCC patients with previously untreated and PD‐L1 positive. Patients were administered camrelizumab with docetaxel and cisplatin every 3 weeks for six cycles, followed by camrelizumab monotherapy every 3 weeks until disease progression or intolerable toxicity. The primary endpoint was occurrence of grade ≥ 3 TRAEs, secondary endpoints included overall survival (OS), progression‐free survival (PFS), and overall response rate (ORR). 45% patients experienced grade ≥ 3 TRAEs, which the most common were anemia (15%), stomatitis (15%), and neutropenia (10%). The most common potential immune‐related adverse events were reactive cutaneous capillary endothelial proliferation (RCCEP; 60%), hypothyroidism (35%), and pneumonitis (15%). No treatment‐related deaths occurred. The median OS, PFS, and ORR was 14.4 months, 5.35 months, and 40.0% respectively. The study also found RCCEP occurrence, lower FOXP3+ cells, and higher density of intratumor tertiary lymphoid structure were associated with improved efficacy. Our data suggest that camrelizumab with docetaxel/cisplatin as first‐line therapy was well tolerable and had potentially favorite efficacy in PD‐L1‐positive patients with R/M OSCC.https://doi.org/10.1002/mco2.312camrelizumabfirst‐line treatmentimmunotherapyoral cancer |
| spellingShingle | Houyu Ju Dongliang Wei Yunteng Wu Yang Liu Qi Ding Mengyu Rui Zongyu Fan Yanli Yao Jingzhou Hu Guoxin Ren A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma MedComm camrelizumab first‐line treatment immunotherapy oral cancer |
| title | A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma |
| title_full | A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma |
| title_fullStr | A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma |
| title_full_unstemmed | A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma |
| title_short | A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma |
| title_sort | pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent metastatic oral squamous cell carcinoma |
| topic | camrelizumab first‐line treatment immunotherapy oral cancer |
| url | https://doi.org/10.1002/mco2.312 |
| work_keys_str_mv | AT houyuju apilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT dongliangwei apilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT yuntengwu apilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT yangliu apilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT qiding apilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT mengyurui apilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT zongyufan apilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT yanliyao apilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT jingzhouhu apilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT guoxinren apilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT houyuju pilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT dongliangwei pilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT yuntengwu pilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT yangliu pilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT qiding pilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT mengyurui pilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT zongyufan pilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT yanliyao pilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT jingzhouhu pilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma AT guoxinren pilotstudyofcamrelizumabwithdocetaxelandcisplatinforthefirstlinetreatmentinrecurrentmetastaticoralsquamouscellcarcinoma |